Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933215 · ClinicalTrials.gov registry record
A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)
A clinical trial, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- 100
- Enrollment target
NCT03933215: Completed study, sponsored by EMD Serono Research & Development Institute.
NCT03933215 is a clinical trial that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03933215 has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (DMDs) approved in the United States (US) for RMS in a real-world setting.
Primary Outcome
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).
Interventions
- DRUG Cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2024-03-30 |
What the finished NCT03933215 record still lists
NCT03933215 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Cladribine is the first listed.
NCT03933215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03933215 about?
NCT03933215 is a clinical study titled "A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)". To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to clad...
What is the current status of trial NCT03933215?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-05-21. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT03933215?
The interventions under investigation include: Cladribine (DRUG).
Who is sponsoring clinical trial NCT03933215?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI